It was in 2000, Dr. Finkelstein told the investigators, that he began using one syringe to draw doses from numerous vials.
Although the in vivo PAE of enrofloxacin was still awaiting further investigation, our data at least suggested that the T>MPC seemed to be the dominant factor in drawing dose intervals since PAE of enrofloxacin was comparably short.
In 2005, investigators found that, in violation of widely accepted practices recommended by the C.D.C., Dr. Finkelstein, 52, who specializes in pain management, was reusing syringes when drawing doses of medicine from vials that hold more than one dose.
MPC values should be considered in drawing dosing strategies since traditional MIC-based dosing level might give rise to treatment failure due to the selection of drug-resistant mutant.
Thus, serum PK/PD parameters were the major data that was based to draw a dosing guideline here (Table 6 and Figure 4).
Before definitive conclusions can be drawn about dose adjustment after ORTs, these results need to be confirmed in a large randomised controlled trial (RCT).
Only three of the included studies offered risk estimates for dose and frequency, making it difficult to draw conclusions of dose effect and frequency effect.
Samples were drawn before dosing and then following the morning dose of olaparib at 30 min, 1, 2, 3, 4, 6, 8 and 12 h on day-7 and day 1 of cycle 1.
Too few cases occurred to draw conclusions regarding dose and incidence of symptomatic hyponatremia.
As shown in Figure 3A, two curves were drawn using dose-response datasets of wild-type and mutant cell lines.
Samples were also drawn pre-dose and at 1 h, on Day 8 of Cycle 1 and Days 1, 8 and 15 of subsequent cycles.
